Sorafenib is Tolerable and Improves Clinical Outcomes in Patients with FLT3-ITD Acute Myeloid Leukemia Prior to Stem Cell Transplant and After Relapse Post-transplant

Overview

Journal Am J Hematol

Specialty Hematology

Date 2014 Jun 6

PMID 24898801

Citations 18

Authors

Sarah L Sammons

Keith W Pratz

B Douglas Smith

Judith E Karp

Ashkan Emadi

Affiliations

Soon will be listed here.

Citing Articles

FLT3 inhibitors as maintenance therapy post allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with FLT3 mutations: A meta-analysis.

Fei X, Zhang S, Gu J, Wang J Cancer Med. 2022; 12(6):6877-6888.

PMID: 36411731 PMC: 10067110. DOI: 10.1002/cam4.5480.

Role of Biomarkers in FLT3 AML.

Nitika , Wei J, Hui A Cancers (Basel). 2022; 14(5).

PMID: 35267471 PMC: 8909069. DOI: 10.3390/cancers14051164.

Post-Transplant Maintenance Therapy for Patients with Acute Myeloid Leukemia: Current Approaches and the Need for More Trials.

Assi R, Masri N, Abou Dalle I, El-Cheikh J, Bazarbachi A J Blood Med. 2021; 12:21-32.

PMID: 33531851 PMC: 7847363. DOI: 10.2147/JBM.S270015.

Advances in Genomic Profiling and Risk Stratification in Acute Myeloid Leukemia.

Richardson D, Foster M, Coombs C, Zeidner J Semin Oncol Nurs. 2019; 35(6):150957.

PMID: 31759819 PMC: 10246438. DOI: 10.1016/j.soncn.2019.150957.

Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors.

Zarakas M, Desai J, Chamilos G, Lionakis M Curr Fungal Infect Rep. 2019; 13(3):86-98.

PMID: 31555394 PMC: 6759856. DOI: 10.1007/s12281-019-00343-9.

References

Ahmed T, Holwerda S, Klepin H, Isom S, Ellis L, Lyerly S . High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly. Leuk Res. 2015; 39(9):945-9. PMC: 4546894. DOI: 10.1016/j.leukres.2015.05.010. View

Ravandi F, Alattar M, Grunwald M, Rudek M, Rajkhowa T, Richie M . Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013; 121(23):4655-62. PMC: 3674666. DOI: 10.1182/blood-2013-01-480228. View

Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A . Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood. 2009; 113(26):6567-71. DOI: 10.1182/blood-2009-03-208298. View

Pratz K, Cho E, Levis M, Karp J, Gore S, McDevitt M . A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia. 2010; 24(8):1437-44. PMC: 2921005. DOI: 10.1038/leu.2010.132. View

Levis M, Small D . FLT3: ITDoes matter in leukemia. Leukemia. 2003; 17(9):1738-52. DOI: 10.1038/sj.leu.2403099. View

Crump M, Hedley D, Kamel-Reid S, Leber B, Wells R, Brandwein J . A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk Lymphoma. 2010; 51(2):252-60. DOI: 10.3109/10428190903585286. View

Ravandi F, Arana Yi C, Cortes J, Levis M, Faderl S, Garcia-Manero G . Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014; 28(7):1543-5. PMC: 4091714. DOI: 10.1038/leu.2014.54. View

Safaian N, Czibere A, Bruns I, Fenk R, Reinecke P, Dienst A . Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. Leuk Res. 2008; 33(2):348-50. DOI: 10.1016/j.leukres.2008.04.017. View

Wilhelm S, Carter C, Tang L, Wilkie D, McNabola A, Rong H . BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64(19):7099-109. DOI: 10.1158/0008-5472.CAN-04-1443. View

10.

Lee S, Paietta E, Racevskis J, Wiernik P . Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation. Am J Hematol. 2009; 84(10):701-2. DOI: 10.1002/ajh.21511. View

11.

Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright J . Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica. 2010; 96(1):62-8. PMC: 3012766. DOI: 10.3324/haematol.2010.030452. View

12.

Levis M . FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?. Hematology Am Soc Hematol Educ Program. 2013; 2013:220-6. PMC: 4714709. DOI: 10.1182/asheducation-2013.1.220. View

13.

Prebet T, Jean E, Autret A, Charbonnier A, Rey J, Etienne A . Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction. Leuk Lymphoma. 2012; 53(11):2186-91. DOI: 10.3109/10428194.2012.685733. View